Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative disease of early childhood, that is peculiarly characterized by the ability of bone marrow progenitors to spontaneously proliferate in vitro, giving rise to granulocytemacrophage colonies. Although the genetic alteration/s leading to JMML development are still unclear, several lines of evidence indicate that the JMML initiating cell (JMML-IC) may belong to the pool of early stem-like hematopoietic progenitors. Increased EVI-1 gene expression has been detected in a number of myeloproliferative disorders including MDS, AML, blast crisis of CML, and more recently in the peripheral blood of some JMML patients. In order to investigate the nature of the cells expressing EVI-1 in JMML patients, we analyzed its expression in CFU-GM obtained from bone marrow and peripheral blood as well as from highly purified CD34 ؉ progenitors. Normal CFU-GM obtained both from bone marrow mononuclear cells and from highly purified CD34 ؉ cells were also analyzed. Overall, our results suggest that the EVI-1 gene may be normally expressed in early hematopoietic progenitor cells and that in JMML patients an expansion of the EVI-1 positive cell population can be revealed within the clonogenic progenitor pool.
Introduction
Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative disorder of early childhood. 1 The occurrence of granulocyte-macrophage colony growth in the absence of hematopoietic factors has been demonstrated as the hallmark of JMML.
2 Although the precise mechanism underlying this spontaneous growth has not been fully elucidated so far, the hypersensitivity to growth factors (mainly GM-CSF and SCF) by JMML bone marrow (BM) progenitors has been suggested as one possible element. [3] [4] [5] Several lines of evidence have indicated that malignant transformation leading to JMML may occur in an immature stem-like cell. [6] [7] [8] Since proliferation and differentiation signals within the hematopoietic system appear to be mediated by a variety of cell-specific transcription factors (TF), we argued that understanding the complex role of TF acting in the early phases of hematopoiesis might provide important insights into the pathogenesis of JMML. In this context we have previously reported high levels of gene expression for GATA-1 and a few related genes in JMML clonogenic progenitors. 7 The ecotropic virus integration site-1 gene (EVI-1) encodes a DNA binding protein with zinc finger domains. 9 Activation of the gene via retroviral insertion 10 or chromosomal rearrangements involving the band 3q26, where the gene is located, has been implicated in murine and human leukemia. [11] [12] [13] [14] [15] It has been reported that the gene is not normally expressed in mature hematopoietic cells, 12, 16 but increased EVI-1 expression has been found in human acute myelogenous leukemia (AML); myelodysplastic syndromes (MDS), blastic crisis of chronic myelogenous leukemia (CML) and more recently in peripheral blood (PB) of JMML patients. [16] [17] [18] [19] In order to investigate the nature of cells expressing the EVI-1 gene in JMML patients, we analyzed its expression in JMML CFU-GM obtained from BM and PB mononuclear cells as well as from highly purified CD34 + progenitors. Our findings indicate that the EVI-1 gene is preferentially expressed in very early progenitor cells and that in JMML patients an expansion of the EVI-1-positive cell population occurs in the clonogenic progenitor pool.
Materials and methods

Patients
The patients included in the present study showed the clinical and laboratory features of JMML at the time of diagnosis, ie hepatosplenomegaly, leukocytosis with monocytosis, BM myeloid hyperplasia, in vitro spontaneous growth of BM progenitors, high levels of HbF and the absence of the t(9;22) translocation. Two of the patients (Nos 6 and 7 in the present series) have been previously reported. 4, 7 Cell preparation and clonogenic assay Peripheral blood (PB) or bone marrow (BM) cells were isolated on Ficoll-Hypaque (Pharmacia, Uppsala, Sweden) density gradient and used for cell cultures. Mononuclear cells were plated in Iscove's modified Dulbecco's medium (IMDM; Gibco, Paisley, UK) with 20% fetal calf serum, with or without 5637 conditioned medium, and 0.33% final concentration of Agar Bacto (Difco Laboratories, Detroit, MI, USA). The conditioned medium from the 5637 tumor cell lines was used as a source of CSF at a final concentration of 10%. BM and PB cells at a density of 5 × 10 4 /ml and 2.5 × 10 5 /ml, respectively, were plated in a volume of 1 ml in Petri dishes in triplicate. CD34 + hematopoietic stem cells were highly purified from PB mononuclear cells of three JMML patients and from normal BM. CD34
+ cells of patients 6 and 10 were studied during relapse, whereas CD34 + cells of patient 11 were analyzed at diagnosis. CD34 + cells were purified by an immunomagnetic system (MiniMacs; Miltenyi Biotec, Bisley, UK) and plated at a density of 10 3 /ml in IMDM, with or without 10% of 5637 conditioned medium; in 0.8% methylcellulose (Stem Cell Tecnologies, Vancouver, BC, Canada).
After a 14-day incubation at 37°C in a fully humidified atmosphere of 5% CO 2 in air, granulocyte-macrophage colony-forming units (CFU-GM) obtained either from mononuclear cells or from CD34
+ cells were scored under an 
Molecular analysis
Total RNA was isolated from BM and PB cell populations and from single CFU-GM colonies (50-100 cells) by the single step method. 20 After in vitro reverse transcription (RT) of RNA from mononuclear cell preparations (10 ng) and from single colonies (the whole amount due to the low number of cells/colony), amplification of the human EVI-1 cDNA sequence 9 was performed. Thirty cycles of amplification were performed with denaturation at 94°C for 1 min, annealing at 60°C for 1 min and extension at 72°C for 1 min using the following primers: sense primer 5′AGGAGTAGAGCCAGTGGGACA3′, antisense primer 5′CATAGAGGGCACTGACTGTAA3′. A second round of PCR (30 cycles) was performed to detect EVI-1 transcripts in CFU-GM colonies by using the following nested primers: sense primer 5′AGCAACGTCGAATCAAGACCT3′, antisense primer, 5′ACTGACTGTAAGAGCTCACTG3′.
For most of the CFU-GM tested, the amount of cDNA 2047 obtained from a single colony was split in two to amplify EVI-1 and ␥-globin genes in the same colony. The oligoprimers and the amplification conditions for ␥-globin cDNA have been previously reported. 7 The specificity of the amplified products was assessed by Southern blot analysis and hybridization with specific internal oligonucleotides after labeling by a non-isotopic system (ECL 3′oligolabeling and detection systems; Amersham, Bucks, UK).
Results and discussion
By RT-PCR, the EVI-1 gene was found to be expressed in PB and BM mononuclear cells isolated from JMML patients in all six cases analyzed (data not shown). These data are in line with recent findings by Gerardt et al 19 who reported increased EVI-1 gene expression in JMML PB mononuclear cells as compared to normal controls. In order to investigate the nature of the cells expressing the EVI-1 gene in BM and PB of JMML patients, we took advantage of the ability of JMML progenitors to give rise to CFU-GM colonies even in the absence of exogenous growth factors. [2] [3] [4] [5] The number of GM colonies obtained from the PB of six JMML patients ranged between 12 ± 2 and 664 ± 47 when 2 × 10 5 /ml mononuclear cells were plated without the addition of growth factors.
We have previously reported that JMML clonogenic cells show a mainly fetal pattern of hemoglobin synthesis, largely expressing ␥-globin gene transcripts. 7 Therefore, we tested the coexpression of EVI-1 and ␥-globin mRNAs in most of the colonies. Figure 1a (left side) shows the results of representative RT-PCR experiments testing the EVI-1 gene expression in CFU-GM obtained from PB mononuclear cells of JMML patients. Most of the JMML colonies (17 out of the 25 tested for coexpression) expressed ␥-globin transcripts, as previously reported, 7 but only a proportion (eight out of 29 total) expressed EVI-1 (Table 1) . In all cases EVI-1 and ␥-globinspecific mRNAs were detected in the same colony.
In three of our patients (Nos 6, 10 and 11) we had the opportunity to analyze highly purified CD34 + cells isolated from PB mononuclear cells that were found to be EVI-1 positive. When these purified CD34 + populations were plated in the absence of added growth factors, they gave rise to a significant colony growth at day 14 in patient 11 (100 colonies by 10 3 /ml plated cells); meanwhile, in the remaining two cases (Nos 6 and 10) the PB CD34 + cells gave rise to a few colonies only. All the colonies generated by PB CD34
+ cells expressed ␥-globin transcripts and most of them also expressed EVI-1 transcripts ( + progenitors expressed EVI-1 (Figure 1b ). These findings confirm and further extend the most recent data reporting the detection of EVI-1 transcripts in normal hematopoietic cells depending on the number of PCR cycles used. 21 If EVI-1 is normally expressed in early progenitor cells, it might be hypothesized that the increased EVI-1 expression detected in the PB of JMML patients might reflect a higher percentage of CD34 + in the PB, possibly related to the expansion of the myeloid compartment usually observed in JMML patients. Recent studies on a SCID mouse model have indicated that the JMML initiating cell (JMML-IC) is one of the more immature cells within the CD34 + pool 8 and several lines of evidence has suggested that both the leukemic monocytes/macrophages and the erythroid cells derive from a common immature progenitor. 7, 22, 23 Our findings indicate that EVI-1 gene expression occurs in early hematopoietic progenitor cells, and that in JMML patients an enrichment in EVI-1-positive cells can be demonstrated within the clonogenic population raising colonies in the absence of exogenous growth factors.
This view is intriguing in that the altered expression of EVI-1 has been shown to interfere with normal response to growth factors by normal mouse hematopoietic progenitors. [24] [25] [26] It is tempting to speculate that abnormalities of EVI-1 expression may contribute to the leukemic phenotype by interfering with the complex network of genes controlling the committment of early progenitors to proliferation and/or differentiation.
